Jacobs & Co. CA Sells 2,254 Shares of Johnson & Johnson (NYSE:JNJ)

Jacobs & Co. CA reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,315 shares of the company's stock after selling 2,254 shares during the period. Jacobs & Co. CA's holdings in Johnson & Johnson were worth $9,007,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of JNJ. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson in the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $32,000. Conquis Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $36,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $1.41 during mid-day trading on Friday, hitting $154.99. The company had a trading volume of 15,529,047 shares, compared to its average volume of 7,975,430. The company has a market capitalization of $372.92 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The stock's 50 day moving average price is $154.31 and its 200-day moving average price is $153.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.36%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.